This segment focuses on the research, development, and clinical evaluation of novel antibody therapeutics for various cancers. Immunome leverages its human memory B cell platform to discover and develop antibodies targeting tumor-derived immune checkpoints and other cancer-related targets. Research and development activities include target identification, antibody discovery, preclinical studies, and clinical trials. The company is actively involved in Phase 1 clinical trials for IM-1021, a ROR1-targeted ADC. This segment aims to improve patient outcomes by providing targeted therapies with the potential to enhance the immune system's ability to fight cancer. Market positioning is based on the development of first-in-class and best-in-class targeted cancer therapies. Future opportunities include expanding the pipeline with additional oncology targets and advancing clinical programs through regulatory approvals and commercialization. Partnerships with companies like AbbVie are crucial for expanding research and development capabilities.

This segment is dedicated to the development of antibody-based therapies for infectious diseases, including COVID-19. Immunome's research and development efforts in this area involve identifying and developing antibodies that neutralize viral infections. The company's lead program, IMM-BCP-01, is an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. Research activities include antibody discovery, preclinical studies, and clinical trials. The goal is to provide effective treatments for infectious diseases and address unmet medical needs. Market positioning is based on the development of innovative antibody therapies. Future opportunities include expanding the pipeline to address other infectious diseases and securing regulatory approvals for commercialization. This segment is critical for addressing global health challenges and improving patient outcomes.